- Home
- SVRA vs GMRE Comparison
SVRA vs GMRE Comparison
Compare SVRA & GMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- GMRE
- Stock Information
- Founded
- SVRA N/A
- GMRE 2011
- Country
- SVRA United States
- GMRE United States
- Employees
- SVRA N/A
- GMRE 26
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- GMRE Real Estate Investment Trusts
- Sector
- SVRA Health Care
- GMRE Real Estate
- Exchange
- SVRA Nasdaq
- GMRE Nasdaq
- Market Cap
- SVRA 458.2M
- GMRE 527.1M
- IPO Year
- SVRA N/A
- GMRE N/A
- Fundamental
- Price
- SVRA $2.85
- GMRE $7.88
- Analyst Decision
- SVRA Buy
- GMRE Strong Buy
- Analyst Count
- SVRA 7
- GMRE 2
- Target Price
- SVRA $9.86
- GMRE $10.88
- AVG Volume (30 Days)
- SVRA 1.0M
- GMRE 533.4K
- Earning Date
- SVRA 03-06-2025
- GMRE 02-25-2025
- Dividend Yield
- SVRA N/A
- GMRE 10.66%
- EPS Growth
- SVRA N/A
- GMRE N/A
- EPS
- SVRA N/A
- GMRE N/A
- Revenue
- SVRA N/A
- GMRE $136,585,000.00
- Revenue This Year
- SVRA N/A
- GMRE N/A
- Revenue Next Year
- SVRA N/A
- GMRE $4.38
- P/E Ratio
- SVRA N/A
- GMRE N/A
- Revenue Growth
- SVRA N/A
- GMRE N/A
- 52 Week Low
- SVRA $2.59
- GMRE $7.33
- 52 Week High
- SVRA $5.70
- GMRE $10.46
- Technical
- Relative Strength Index (RSI)
- SVRA 45.63
- GMRE 46.19
- Support Level
- SVRA $2.62
- GMRE $7.75
- Resistance Level
- SVRA $2.88
- GMRE $8.20
- Average True Range (ATR)
- SVRA 0.19
- GMRE 0.20
- MACD
- SVRA 0.02
- GMRE 0.02
- Stochastic Oscillator
- SVRA 40.37
- GMRE 40.35
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is a Maryland corporation engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.